Puerto RicoHealthcare and life sciences2020 – ongoing

CorePlus

Galen AI support for prostate and breast pathology

CorePlus pathologists corrected diagnoses for over 150 patients with AI input, according to Ibex

WorkingVendor case studyVendor ↗

Problem

Growing diagnostic workloads increased pressure on pathologists. Manual biopsy review could miss cancer.

Approach

CorePlus deployed Ibex's prostate AI in 2020 for routine quality control. It added breast pathology support and subsequently expanded Galen to primary diagnosis. Pathologists used its findings to review suspected cancer and support reporting.

Results

over 150patients whose diagnoses pathologists corrected using AI input, according to IbexVendor case study[1]

over 10,000cases diagnosed using Galen, according to IbexVendor case study[1]

more than 125,000pathology slides analysed using the deployed technologies, according to IbexVendor case study[1]

Takeaway

CorePlus expanded AI from a second check into primary diagnostic work. The supplier did not quantify turnaround improvements.

Sources

CorePlus Shows Success With Real-World Utilization of Ibex's AI Platform for Routine Cancer Diagnosis, Supporting Improved Patient Outcomes
Ibex Medical Analytics via PR Newswire10 Oct 2023Vendor publication
First U.S. lab implements AI-based solution for cancer detection in pathology
Ibex Medical Analytics1 Sep 2020Vendor publication

Source summaries

[1]Ibex Medical Analytics via PR Newswire10 Oct 2023

Ibex reported the case and slide volumes and corrections affecting over 150 patients. CorePlus had extended Galen into primary diagnosis.

[2]Ibex Medical Analytics1 Sep 2020

Ibex announced deployment at CorePlus in Puerto Rico. It said all prostate cases received AI evaluation in routine practice.

Full details are in the original sources.

Added 1 Nov 2026 · Updated 1 Nov 2026